Aromatase inhibitors and their future role in post-menopausal women with early breast cancer
1998

Aromatase Inhibitors in Early Breast Cancer

publication Evidence: moderate

Author Information

Author(s): PE L0nning

Primary Institution: Haukeland University Hospital, Bergen, Norway

Hypothesis

Can aromatase inhibitors like anastrozole provide benefits over tamoxifen in treating early breast cancer in post-menopausal women?

Conclusion

Anastrozole shows promise in improving outcomes for post-menopausal women with early breast cancer compared to traditional treatments.

Supporting Evidence

  • Anastrozole increased median survival time from 22.5 months to 26.7 months compared to megestrol acetate.
  • The 2-year survival rate improved from 46.3% to 56.1% with anastrozole.
  • Anastrozole causes significantly less weight gain than megestrol acetate.

Takeaway

This study looks at a new medicine called anastrozole that might help women with early breast cancer feel better and live longer.

Methodology

Overview analysis of two prospective, randomized, phase III trials comparing anastrozole with megestrol acetate.

Limitations

The long-term effects of anastrozole on bone density and lipid profiles are still being studied.

Participant Demographics

Post-menopausal women with early breast cancer.

Statistical Information

P-Value

0.002

Statistical Significance

p=0.002

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication